Though many of its pipeline assets are cancer related, IGM has imvotamab that targets CD20 and CD3 proteins. It is in phase 1 for systemic lupus erythematosus, rheumatoid arthritis, and idiopathic ...

Imvotamab is a T cell engaging antibody that targets CD20 and CD3 proteins. IGM Biosciences was evaluating it in three trials, the third being a treatment for myositis, a rare autoimmune disease ...

Wedbush restated their neutral rating on shares of IGM Biosciences (NASDAQ:IGMS – Free Report) in a report issued on Friday ...

Royal Bank of Canada lowered shares of IGM Biosciences (NASDAQ:IGMS – Free Report) from an outperform rating to a sector ...

High serum CXCL13 levels are predictive of treatment failure with first-line MTX among patients with early RA.